Literature DB >> 3528057

Identification and management of the patient at high risk for wound infection.

G D Becker.   

Abstract

Despite the use of perioperative antibiotics, wound infection remains a major source of morbidity after contaminated head and neck cancer surgery. Most adjunctive methods designed to control wound infection include techniques to reduce bacterial wound contamination. Additional methods include predicting the high risk patient and the bacteriology of subsequent wound infection, which allows antibiotic prophylaxis to be used on a selective basis. This article reviews relevant experimental and clinical data that evaluated these methods. Based on these results, as well as personal observations, guidelines are suggested for controlling wound infection in patients undergoing contaminated head and neck surgery.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3528057     DOI: 10.1002/hed.2890080313

Source DB:  PubMed          Journal:  Head Neck Surg        ISSN: 0148-6403


  5 in total

1.  Prevention and Treatment of Postsurgical Head and Neck Infections.

Authors:  Rebecca Fraioli; Jonas T. Johnson
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

2.  Advances in chemoprophylaxis for head and neck surgical wound infections.

Authors:  K T Robbins
Journal:  West J Med       Date:  1989-04

Review 3.  Perioperative Care of Free Flap Patients.

Authors:  Aurora Vincent; Raja Sawhney; Yadranko Ducic
Journal:  Semin Plast Surg       Date:  2019-03-08       Impact factor: 2.314

4.  Factors Affecting Postoperative Complications After Reconstructive Surgery in Oral Carcinoma Patients: A Prospective Study of 100 Patients.

Authors:  Prateek Vijay Jain; Bhavesh Bang; Kapila Manikantan; Tiash Sinha; Gautam Biswas; Pattatheyil Arun
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-03-19

5.  Wound care management: proper protocol differs from athletic trainers' perceptions.

Authors:  M S Goldenberg
Journal:  J Athl Train       Date:  1996-01       Impact factor: 2.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.